AMA announces CPT update for pediatric COVID-19 vaccine candidate

Oct. 12, 2021

The American Medical Association (AMA) announced that the Current Procedural Terminology (CPT) code set has been updated by the CPT Editorial Panel to include vaccine and administration codes for pediatric doses of the COVID-19 vaccine developed by Pfizer and BioNTech.

The provisional CPT codes will be effective for use on the condition that the two-dose regimen for the prevention of COVID-19 in children ages 5 to 11 receives approval or emergency use authorization from the U.S. Food and Drug Administration (FDA). The AMA said it is publishing the CPT code update now to ensure electronic systems across the U.S. healthcare system are prepared in advance for the potential FDA approval or authorization.

The development of vaccine-specific CPT codes has clinically distinguished each coronavirus vaccine and dosing schedule for better tracking, reporting and analysis that supports data-driven planning and allocation. COVID-19 vaccines from AstraZeneca, Janssen (Johnson & Johnson), Moderna, Novavax and Pfizer-BioNTech have previously been issued unique CPT codes.

For quick reference, the new vaccine and administration codes assigned to the pediatric doses of Pfizer and BioNTech’s COVID-19 vaccine are 91307 (product code) and 0071A and 0072A (administration codes).

Visit the AMA for more news